Compare EDSA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDSA | COCH |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | Canada | United States |
| Employees | N/A | 47 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.1M | 53.4M |
| IPO Year | 2018 | N/A |
| Metric | EDSA | COCH |
|---|---|---|
| Price | $5.68 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $6.00 |
| AVG Volume (30 Days) | 95.4K | ★ 783.4K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.36 |
| 52 Week High | $20.32 | $1.89 |
| Indicator | EDSA | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 48.14 |
| Support Level | $4.87 | $0.64 |
| Resistance Level | $6.58 | $0.74 |
| Average True Range (ATR) | 0.53 | 0.07 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 1.63 | 25.96 |
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.